Three Big Reasons to Own Johnson & Johnson (JNJ) Stock

Of course, there are more lucrative options out there. You could invest in Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) or VIVUS, Inc. (NASDAQ:VVUS), which have developed obesity medications. Both Belviq and Qsymia, each company’s respective medicine, have been approved by the FDA and hold great potential for investors. But because of insurers being slow to pick up coverage, or labeling issues with the DEA, sales have yet to take off.

A much safer route would be to invest in Johnson & Johnson (NYSE:JNJ) stock. Although the company might not have a breakthrough medicine for obesity right now, it has enough cash to finance major research and development in the future. And the company also has a global reach, which becomes evermore important as the ills of Western living start to spread across the globe.

A Foolish approach
I’ve been investing in Johnson & Johnson (NYSE:JNJ) stock since August 2011. Since then, the stock has returned 45% — beating the market by 11 percentage points. But I still think any investor looking for exposure to health care would be wise to consider buying shares of Johnson & Johnson.

The article 3 Big Reasons to Own Johnson & Johnson Stock originally appeared on Fool.com and is written by Brian Stoffel.

Fool contributor Brian Stoffel owns shares of Johnson & Johnson. The Motley Fool recommends Johnson & Johnson. The Motley Fool owns shares of General Electric Company and Johnson & Johnson.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.